Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for allopurinol
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on allopurinol or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on allopurinol and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Association of Chronic Kidney Disease With Allopurinol Use in Gout Treatment 30304329 2018 11 05 2168-6114 178 11 2018 Nov 01 JAMA internal medicine JAMA Intern Med Association of Chronic Kidney Disease With Allopurinol Use in Gout Treatment. 1526-1533 10.1001/jamainternmed.2018.4463 Clinicians are often cautious about use of allopurinol in patients with gout when renal function declines. To assess the association of allopurinol use in gout with the risk of developing chronic kidney disease (...) stage 3 or higher. A time-stratified propensity score-matched, population-based, prospective cohort study of individuals with newly diagnosed gout who initiated allopurinol (≥300 mg/d) compared with those who did not initiate allopurinol, using the Health Improvement Network (THIN), a United Kingdom general practitioner electronic health records database, was carried out. The data were analyzed using Cox proportional hazards regression. Among adults aged 18 to 89 years with newly diagnosed gout, we
Assessment of Cardiovascular Risk in Older Patients with Gout Initiating Febuxostat versus Allopurinol: A Population-Based Cohort Study 29899013 2018 07 12 1524-4539 2018 Jun 13 Circulation Circulation Assessment of Cardiovascular Risk in Older Patients with Gout Initiating Febuxostat versus Allopurinol: A Population-Based Cohort Study. CIRCULATIONAHA.118.033992 10.1161/CIRCULATIONAHA.118.033992 Background -Hyperuricemia and gout are associated with increased risk of cardiovascular disease (CVD (...) ). Xanthine oxidase inhibitors (XOI), allopurinol and febuxostat, are the mainstay of urate lowering treatment for gout and may have different effects on cardiovascular risk in patients with gout. Methods -Using U.S. Medicare claims data (2008-2013), we conducted a cohort study for comparative cardiovascular safety of initiating febuxostat versus allopurinol among gout patients aged ≥65 years. The primary outcome was a composite endpoint of hospitalization for myocardial infarction (MI) or stroke
Maternal Allopurinol Prevents Cardiac Dysfunction in Adult Male Offspring Programmed by Chronic Hypoxia During Pregnancy 30354714 2018 11 14 1524-4563 72 4 2018 Oct Hypertension (Dallas, Tex. : 1979) Hypertension Maternal Allopurinol Prevents Cardiac Dysfunction in Adult Male Offspring Programmed by Chronic Hypoxia During Pregnancy. 971-978 10.1161/HYPERTENSIONAHA.118.11363 Integrating functional and molecular levels, we investigated the effects of maternal treatment with a xanthine oxidase (...) inhibitor on the programming of cardiac dysfunction in adult offspring using an established rat model of hypoxic pregnancy. Female Wistar rats were divided into normoxic or hypoxic (13% O 2 ) pregnancy±maternal allopurinol treatment (30 mg kg -1 d -1 ). At 4 months, hearts were isolated from 1 male per litter per outcome variable to determine cardiac function and responses to ischemia-reperfusion in a Langendorff preparation. Sympathetic dominance, perfusate CK (creatine kinase) and LDH (lactate
Allopurinol Top results for allopurinol - Trip Database or use your Google+ account Find evidence fast My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search (...) button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for allopurinol The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory
Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. Background Cardiovascular risk is increased in patients with gout. We compared cardiovascular outcomes associated with febuxostat, a nonpurine xanthine oxidase inhibitor, with those associated with allopurinol, a purine base analogue xanthine oxidase inhibitor, in patients with gout and cardiovascular disease. Methods We conducted a multicenter, double-blind, noninferiority trial involving patients with gout (...) and cardiovascular disease; patients were randomly assigned to receive febuxostat or allopurinol and were stratified according to kidney function. The trial had a prespecified noninferiority margin of 1.3 for the hazard ratio for the primary end point (a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or unstable angina with urgent revascularization). Results In total, 6190 patients underwent randomization, received febuxostat or allopurinol, and were followed for a median
Effect of administration of allopurinol on postoperative outcomes in patients undergoing intracardiac repair of tetralogy of Fallot 29245201 2017 12 16 1097-685X 155 1 2018 Jan The Journal of thoracic and cardiovascular surgery J. Thorac. Cardiovasc. Surg. Effect of administration of allopurinol on postoperative outcomes in patients undergoing intracardiac repair of tetralogy of Fallot. 335-343 S0022-5223(17)31881-0 10.1016/j.jtcvs.2017.08.115 To determine effects of allopurinol administration (...) on outcomes following intracardiac repair of tetralogy of Fallot (TOF). Fifty patients undergoing TOF repair were randomized to 2 groups of 25 each: the allopurinol group (n = 25) and the placebo group (n = 25). Postoperatively, inotropic score, rhythm, duration of mechanical ventilation, cardiac output, intensive care unit (ICU) stay, and hospital stay were assessed. Plasma troponin-I, superoxide dismutase (SOD), interleukin (IL) 1-ß, IL-6, and malondialdehyde were measured serially. Inotropic score
Treatment with Allopurinol is Associated with Lower Risk of Acute Kidney Injury in Patients with Gout: A Retrospective Analysis of a Nested Cohort 28956324 2018 11 13 2198-6576 4 2 2017 Dec Rheumatology and therapy Rheumatol Ther Treatment with Allopurinol is Associated with Lower Risk of Acute Kidney Injury in Patients with Gout: A Retrospective Analysis of a Nested Cohort. 419-425 10.1007/s40744-017-0082-2 Gout is characterized by recurrent episodes of acute inflammation of joint structures (...) with increased risk of AKI. Interestingly, patients who had been previously prescribed allopurinol showed a lower risk of acute renal events. In addition to classic risk factors, the number of flares and extensive joint distribution were associated with higher risk for renal injury in patients with gout, while previous prescription of allopurinol was associated with lower risk. Perez-Ruiz Fernando F http://orcid.org/0000-0002-5268-1894 Rheumatology Division, Hospital Universitario Cruces, University
Starting allopurinol in acute gout Starting allopurinol in acute gout » Morsels of Evidence Search Evidence based medicine for general practitioners « » Oct 30 Starting allopurinol in acute gout Categories: , by Journal reference: Hill EM, Sky K, Sit M, Collamer A, Higgs J. Does starting allopurinol prolong acute treated gout? A randomized clinical trial. J Clin Rheumatol 2015;21(3):120-5. Link: Published: April 2015 Evidence cookie says… It is unclear what effect starting allopurinol in acute (...) has on symptoms, due to the lack of good evidence. it may be preferable to avoid starting allopurinol in an acute attack this should not be a dogmatic stance Clinical scenario Zhongyu, a 50-year-old allied health practitioner presented with a recurrence of podagra – he’d had several attacks of acute gout in past year. As we spoke about preventive therapy, I remembered an online discussion at GPs Down Under – is the recommendation against starting allopurinol in acute gout evidence-based? Clinical
Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study. OBJECTIVE: To evaluate the use of prospective screening for the HLA-B*58:01 allele to identify Taiwanese individuals at risk of severe cutaneous adverse reactions (SCARs) induced by allopurinol treatment. DESIGN: National prospective cohort study. SETTING: 15 medical centres in different regions of Taiwan, from July 2009 to August 2014. PARTICIPANTS: 2926 (...) people who had an indication for allopurinol treatment but had not taken allopurinol previously. Participants were excluded if they had undergone a bone marrow transplant, were not of Han Chinese descent, and had a history of allopurinol induced hypersensitivity. DNA purified from 2910 participants' peripheral blood was used to assess the presence of HLA-B*58:01. MAIN OUTCOME MEASURES: Incidence of allopurinol induced SCARs with and without screening. RESULTS: Participants who tested positive for HLA
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Human Leukocyte Antigen-B (HLA-B) Genotype and Allopurinol Dosing Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Human Leukocyte Antigen B (HLA-B) Genotype and Allopurinol Dosing: 2015 Update YSaito 1 ,LKStamp 2 ,KECaudle 3 ,MSHershfield 4 ,EMMcDonagh 5 ,JTCallaghan 6,7,8 ,WTassaneeyakul 9 , TMushiroda 10 ,NKamatani 11 ,BRGoldspiel 12 ,EJPhillips 13,14 ,TEKlein 5 andMTMLee 15,16,17 The Clinical (...) and information that would modify prescribing recommendations pertaining to gene speci?c alleles and nomenclature are updated periodically on the PharmGKB website. Furthermore, published CPIC guidelines are currently systematically reviewed for updates periodically. The CPIC Guideline for HLA-B Genotype and Allopurinol Dosing was originally published in February 2013. 2 To update this guideline, we conducted a focused review of the literature published between 1966 to October 2014 on HLA genotype
Allopurinol for the treatment of chronic kidney disease: a systematic review Allopurinolforthetreatmentofchronic kidneydisease:asystematicreview Nigel Fleeman, 1* Gerlinde Pilkington, 1 Yenal Dundar, 1 Kerry Dwan, 1 Angela Boland, 1 Rumona Dickson, 1 Hameed Anijeet, 2 Tom Kennedy 2 and Jason Pyatt 2 1 Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK 2 Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK *Corresponding author Declared (...) . Allopurinol (Zyloric ® , Aspen) is a drug commonly used to treat hyperuricaemia in patients with gout. Evidence is emerging that it may also have a role to play in slowing down the progression of CKD and reducing the risk of CVD. Objectives The aim of this systematic review was to address the following research question: does allopurinol reduce mortality, the progression of chronic kidney disease or cardiovascular risk in people with CKD? Given the importance of adverse events (AEs) (common and rare
Allopurinol for the treatment of chronic kidney disease: a systematic review Allopurinol for the treatment of chronic kidney disease: a systematic review Allopurinol for the treatment of chronic kidney disease: a systematic review Fleeman N, Pilkington G, Dundar Y, Dwan K, Boland A, Dickson R, Anijeet H, Kennedy T, Pyatt J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been (...) made for the HTA database. Citation Fleeman N, Pilkington G, Dundar Y, Dwan K, Boland A, Dickson R, Anijeet H, Kennedy T, Pyatt J. Allopurinol for the treatment of chronic kidney disease: a systematic review. Health Technology Assessment 2014; 18(40): 106 Authors' objectives The aim of this systematic review was to address the following research question: does allopurinol reduce mortality, the progression of chronic kidney disease or cardiovascular risk in people with CKD? Given the importance
Allopurinol USE OF ALLOPURINOL IN PREGNANCY 0344 892 0909 USE OF ALLOPURINOL IN PREGNANCY (Date of issue: September 2014 , Version: 1 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Allopurinol is a hypoxanthine analogue that inhibits xanthine (...) oxidase, thus decreasing the production of uric acid. Allopurinol is used primarily in the management or prophylaxis of gout, uric acid and calcium oxalate renal calculi, and hyperuricaemia associated with cancer chemotherapy. Allopurinol is also occasionally used in the treatment of inflammatory bowel disease and as a thiopurine adjunct in renal transplant recipients. The conditions for which allopurinol is used are generally rare in women of childbearing age, and human data on allopurinol use during
Randomized Controlled Trial of Febuxostat Versus Allopurinol or Placebo in Individuals with Higher Urinary Uric Acid Excretion and Calcium Stones 23929928 2013 11 08 2014 07 01 2016 12 15 1555-905X 8 11 2013 Nov Clinical journal of the American Society of Nephrology : CJASN Clin J Am Soc Nephrol Randomized controlled trial of febuxostat versus allopurinol or placebo in individuals with higher urinary uric acid excretion and calcium stones. 1960-7 10.2215/CJN.01760213 Higher urinary uric acid (...) excretion is a suspected risk factor for calcium oxalate stone formation. Febuxostat, a xanthine oxidoreductase inhibitor, is effective in lowering serum urate concentration and urinary uric acid excretion in healthy volunteers and people with gout. This work studied whether febuxostat, compared with allopurinol and placebo, would reduce 24-hour urinary uric acid excretion and prevent stone growth or new stone formation. In this 6-month, double-blind, multicenter, randomized controlled trial
Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial 23098865 2012 10 26 2013 03 28 2013 11 21 1555-7162 125 11 2012 Nov The American journal of medicine Am. J. Med. Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. 1126-1134.e7 10.1016/j.amjmed.2012.05.025 S0002-9343(12)00553-0 Streamlining the initiation of allopurinol could result in a cost benefit for a common medical problem (...) and obviate the perception that no treatment is required once acute attacks have resolved. Our objective was to test the hypothesis that there is no difference in patient daily pain or subsequent attacks with early versus delayed initiation of allopurinol for an acute gout attack. A total of 57 men with crystal-proven gout were randomized to allopurinol 300 mg daily or matching placebo for 10 days. All subjects received indomethacin 50 mg 3 times per day for 10 days, a prophylactic dose of colchicine 0.6
Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. 20542554 2010 07 08 2010 08 18 2016 10 19 1474-547X 375 9732 2010 Jun 19 Lancet (London, England) Lancet Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. 2161-7 10.1016/S0140-6736(10)60391-1 Experimental evidence suggests that xanthine oxidase inhibitors can reduce myocardial (...) oxygen consumption for a particular stroke volume. If such an effect also occurs in man, this class of inhibitors could become a new treatment for ischaemia in patients with angina pectoris. We ascertained whether high-dose allopurinol prolongs exercise capability in patients with chronic stable angina. 65 patients (aged 18-85 years) with angiographically documented coronary artery disease, a positive exercise tolerance test, and stable chronic angina pectoris (for at least 2 months) were recruited
A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout 18633127 2009 05 13 2009 06 24 2014 07 30 1468-2060 68 6 2009 Jun Annals of the rheumatic diseases Ann. Rheum. Dis. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. 892-7 10.1136/ard.2008.091462 (...) To compare the efficacy and tolerability of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day used to attain a target serum urate concentration (sUr) < or =0.30 mmol/l (5 mg/dl). A randomised, controlled, open-label, multicentre trial in gout patients with renal function defined as a calculated creatinine clearance > or =50 ml/min. Patients were treated with 300 mg allopurinol or 100 mg benzbromarone once a day (stage 1). If sUr < or =0.30 mmol/l was not attained after 2 months, the dose
The Effectiveness of Newly FDA Approved Uloric (Febuxostat) Versus the Conventionally Used Zyloprim (Allopurinol) in Treatment of Hyperuricemia and Chronic Gout in the Adult Population "The Effectiveness of Newly FDA Approved Uloric (Febuxostat) Versus the" by Kyle K. Ohisa < > > > > > Title Author Date of Award 8-15-2009 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Mark Pedemonte, MD Second Advisor Rob Rosenow PharmD, OD Third Advisor (...) million adults aged 20 years old and older. Many challenges are faced with the treatment of gout, however, the mainstay of hypouricemic treatment has been the conventional use of allopurinol. In February of 2009, the FDA approved a new medication, Uloric (febuxostat), which claimed to be more effective than Zylporim (allopurinol) for chronic sufferers of gout who have long been dissatisfied with previously available options in the treatment of hyperuricemia. Hypothesis: Patients who did not receive